US president Donald Trump has announced an executive order aimed at reducing US prescription drug costs by 30-80%. The policy would align US drug prices with the lowest prices paid internationally and ...

While Prasad’s views may not align with many of the FDA’s traditional policies, they do fit into a broader MAHA agenda of ...

The United States Food and Drug Administration has chosen Dr Vinay Prasad to lead its Center for Biologics Evaluation and Research.

Axon named Tina Hahn as president and managing partner. Bristol Myers Squibb promoted Cari Gallman to EVP, general counsel ...

Dr. Vinay Prasad, a prominent critic of the pharmaceutical industry and the Food and Drug Administration, has been named to ...

Wel­come back to End­points Week­ly — thanks for start­ing your Sat­ur­day with us. It was a busy week in the bio­phar­ma world. FDA Com­mis­sion­er Mar­ty Makary … ...

A former critic of FDA and Pharma will now oversee the regulation of costly and complicated biologics like vaccines, gene therapies, and blood supply.

In the wake of the high-profile departure of Peter Marks, M.D., Ph.D., the FDA has a new leader for its Center for Biologics ...

FDA commissioner Marty Makary told FDA staff in an email that Prasad, “brings a great set of skills, energy, and competence ...